Journal
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Volume 13, Issue 5, Pages 2255-2258Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2017.4229
Keywords
chronic immune thrombocytopenic purpura; human umbilical cord-derived mesenchymal stem cells; intravenous infusion; safety; efficacy
Categories
Funding
- National High Technology Research and Development Program, 863 Program [2011AA020101, 2012A020905]
Ask authors/readers for more resources
Four patients with chronic refractory immune thrombocytopenic purpura (ITP) received human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). The hUC-MSC dose was 5x10(7) to 1x10(8). Complete remission (CR) was achieved in three patients in 12 months and one patient in 24 months. Three patients received the second hUC-MSC transplantation with the same dose. The median time between hUC-MSC transplantation and response was 12.5 days (range, 7-16). There were no severe adverse events during and post hUC-MSC transplantation. During follow-up (median, 17 months; range, 13-24) no other immuno-suppressive drugs were used post-first hUC-MSCs transplantation. In conclusion, hUC-MSC transplantation is a reasonable salvage treatment in chronic refractory ITP. Prospective randomized large-scale clinical trials are needed to further elucidate the efficacy of hUC-MSCs transplantation therapy on ITP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available